1.
|
Section
5.1c of the 3G4 AGREEMENT shall be revised to read in its entirety as
follows:
|
2.
|
Section
5.1f of the 3G4 AGREEMENT shall be deleted in its entirety and subsequent
Sections 5.1g, 5.1h, and 5.1i shall be renumbered 5.1f, 5.1g and 5.1h
respectively.
|
3.
|
Except
as expressly provided in this AMENDMENT ONE, all other terms, conditions
and provisions of the 3G4 AGREEMENT shall continue in full force and
effect as provided therein.
|
4.
|
This
AMENDMENT ONE may be executed in counterparts, each of which shall be
deemed original, and in aggregate shall constitute one and the same
instrument. Transmission by facsimile, email or other form of
electronic transmission of an executed counterpart of this AMENDMENT ONE
shall be deemed to constitute due and sufficient delivery of such
counterpart.
|
BOARD
OF REGENTS OF
THE
UNIVERSITY OF TEXAS SYSTEM
|
PEREGRINE
PHARMACEUTICALS, INC.
|
By /s/ John A.
Roan
|
By /s/ Steven W.
King
|
John
A. Roan
|
Steven
W. King
|
Executive
Vice President for Business Affairs
|
President
and CEO
|
UT
Southwestern Medical Center at Dallas
|
|
Date
7/23/09
|
Date
7-10-09
|
Approved
as to Content:
|
By /s/ Dennis K.
Stone
|
Dennis
K. Stone, M.D.
|
Vice
President for Technology Development
|
UT
Southwestern Medical Center at Dallas
|
Date
7/21/09
|